07.14.15
Headquarters: Brentford, Middlesex, UK
twitter.com/GSK
www.gsk.com
TOP SELLING DRUGS
GlaxoSmithKline (GSK) said challenging trading conditions, particularly in the U.S. primary care market led to sales declining 8% for the year to $30.8 billion.
The standout event of the year for GSK was the major three-part transaction with Novartis involving its consumer healthcare, vaccines, and oncology businesses. The two companies will create a new consumer healthcare business, for which GSK will have majority control with an equity interest of 63.5%.
GSK will acquire Novartis’ global vaccines business—excluding influenza vaccines—for an initial cash consideration of $5.25 billion and subsequent potential milestone payments of as much as $1.8 billion, as well as royalties on sales.
Finally, Novartis will acquire GSK’s marketed oncology portfolio, related R&D activities, and rights to its AKT inhibitor and future products, for approximately $16 billion.
The Novartis OTC portfolio is highly complementary to GSK’s and has many well-known brands such as Voltaren, Excedrin, Otrivin and Theraflu.
Also during the year, Avalon Ventures launched two new companies through its collaboration with GSK—Silarus Therapeutics and Thyritope Biosciences. Each will receive as much as $10 million in financing and R&D support from Avalon and GSK. Both companies will be located at COI Pharmaceuticals in San Diego, an innovation center established by Avalon to provide an R&D facility and operational support to its life science portfolio companies.
Clovis Oncology entered into a clinical trial collaboration with GSK to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib in combination with trametinib is planned for 1H15. The trial will assess the safety and activity of the combination in patients with EGFR mutant NSCLC who were previously treated with an EGFR tyrosine kinase inhibitor (TKI).
Roivant Neurosciences Ltd. entered into an agreement with GSK to acquire SB742457, a selective 5-HT6 receptor antagonist with the potential to improve cognition and function in multiple central nervous system disorders.
Following approvals received in 2013 for respiratory products Breo Ellipta and Anoro Ellipta, Tafinlar and Mekinist in oncology and Tivicay in HIV, GSK received four further approvals in 2014: Incruse Ellipta and Arnuity Ellipta in respiratory, Triumeq in HIV and Tanzeum for type 2 diabetes. GSK is awaiting FDA decisions on Breo Ellipta for use in asthma and mepolizumab, a first-in-class anti-IL5 treatment for severe eosinophilic asthma. GSK says this year it expects as many as 25 Phase II or III starts.
In its advanced pipeline GSK sees significant potential, for example, from its vaccine to prevent shingles, a triple combination therapy for COPD and a new long acting HIV treatment, cabotegravir. In addition to these GSK has a number of exciting early stage assets in therapy areas such as immuno-inflammation, immuno-oncology and cardiovascular disease and a number of prophylactic and therapeutic vaccine candidates.
twitter.com/GSK
www.gsk.com
Headcount: | 98,000 | |
Year Established: | 2002 | |
Revenues: | $37,960 | (-9%) |
Pharma Revenues: | $30,806 | (-8%) |
Net Income: | $4,671 | (-47%) |
R&D: | $5,693 | (-8%) |
TOP SELLING DRUGS
Drug | Indication | 2014 Sales | (+/-%) |
Seretide/Advair | asthma, COPD | $6,978 | -16% |
Infanrix, Pediarix | pediatric vaccine | $1,366 | 1% |
Avodart | enlarged prostate | $1,328 | -1% |
Epzicom/Kivexa | HIV | $1,267 | 6% |
Flixotide/Flovent | respiratory | $1,158 | -7% |
Ventolin | asthma | $1,097 | 9% |
Augmentin | antibacterial | $945 | -4% |
Lamictal | anti-epileptic | $875 | 0% |
GlaxoSmithKline (GSK) said challenging trading conditions, particularly in the U.S. primary care market led to sales declining 8% for the year to $30.8 billion.
The standout event of the year for GSK was the major three-part transaction with Novartis involving its consumer healthcare, vaccines, and oncology businesses. The two companies will create a new consumer healthcare business, for which GSK will have majority control with an equity interest of 63.5%.
GSK will acquire Novartis’ global vaccines business—excluding influenza vaccines—for an initial cash consideration of $5.25 billion and subsequent potential milestone payments of as much as $1.8 billion, as well as royalties on sales.
Finally, Novartis will acquire GSK’s marketed oncology portfolio, related R&D activities, and rights to its AKT inhibitor and future products, for approximately $16 billion.
The Novartis OTC portfolio is highly complementary to GSK’s and has many well-known brands such as Voltaren, Excedrin, Otrivin and Theraflu.
Also during the year, Avalon Ventures launched two new companies through its collaboration with GSK—Silarus Therapeutics and Thyritope Biosciences. Each will receive as much as $10 million in financing and R&D support from Avalon and GSK. Both companies will be located at COI Pharmaceuticals in San Diego, an innovation center established by Avalon to provide an R&D facility and operational support to its life science portfolio companies.
Clovis Oncology entered into a clinical trial collaboration with GSK to evaluate a novel combination therapy targeting mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC). The Phase 1/2 trial of rociletinib in combination with trametinib is planned for 1H15. The trial will assess the safety and activity of the combination in patients with EGFR mutant NSCLC who were previously treated with an EGFR tyrosine kinase inhibitor (TKI).
Roivant Neurosciences Ltd. entered into an agreement with GSK to acquire SB742457, a selective 5-HT6 receptor antagonist with the potential to improve cognition and function in multiple central nervous system disorders.
Following approvals received in 2013 for respiratory products Breo Ellipta and Anoro Ellipta, Tafinlar and Mekinist in oncology and Tivicay in HIV, GSK received four further approvals in 2014: Incruse Ellipta and Arnuity Ellipta in respiratory, Triumeq in HIV and Tanzeum for type 2 diabetes. GSK is awaiting FDA decisions on Breo Ellipta for use in asthma and mepolizumab, a first-in-class anti-IL5 treatment for severe eosinophilic asthma. GSK says this year it expects as many as 25 Phase II or III starts.
In its advanced pipeline GSK sees significant potential, for example, from its vaccine to prevent shingles, a triple combination therapy for COPD and a new long acting HIV treatment, cabotegravir. In addition to these GSK has a number of exciting early stage assets in therapy areas such as immuno-inflammation, immuno-oncology and cardiovascular disease and a number of prophylactic and therapeutic vaccine candidates.
GSK may have dropped a place in the Top 25 this year but it has certainly been busy in terms of acquisitions, collaborations and divesting parts of its business. GSK began the year acquiring the rest of GlyconVaxyn for the sum of $190 million. This was followed in March by a deal with Novartis acquiring most of its vaccine division, creating a new consumer health care joint venture, and selling off its oncology business. Around the same time GSK sold its opiates business to India-based Sun Pharma. Finally, Irish-based Perrigo recently announced that it has acquired a portfolio of GSK’s well-known OTC brands. The end of 2014 wasn’t kind to GSK after the whopping fine and bad publicity that followed the China bribery scandal, but the company is working hard to move on in 2015. With the filing of applications in the U.S. and Europe late last year for mepolizumab, its injectable for the treatment of severe asthma, it may have another blockbuster in the making. Having made a very public announcement to illustrate improvements to its modus operandi it is still going to have to do some polishing to shine up its corporate image. —Adele Graham-King |